Related Experiment Video
Updated: Jul 13, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Anti-immunoglobulin E therapy with omalizumab for asthma
Leslie Hendeles1, Christine A Sorkness
1Department of Pharmacy Practice, College of Pharmacy and Pediatric Pulmonary Division, College of Medicine, University of Florida, Gainesville, FL, USA. hendeles@cop.ufl.edu
The Annals of Pharmacotherapy
|August 19, 2007
Summary
Anti-immunoglobulin E (anti-IgE) therapy, specifically omalizumab, effectively treats IgE-mediated asthma in patients inadequately controlled by standard treatments. This therapy improves symptom control and reduces reliance on corticosteroids, though cost and inconvenience require consideration.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Immunoglobulin E (IgE) plays a critical role in the pathophysiology of asthma, driving airway inflammation.
- Omalizumab is a targeted biologic therapy designed to neutralize IgE.
Purpose of the Study:
- To review and evaluate the efficacy, tolerability, and cost-effectiveness of anti-immunoglobulin E (anti-IgE) therapy for asthma management.
- To assess the role of omalizumab in patients with inadequately controlled allergic asthma.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through PubMed (1989-2007) using keywords 'omalizumab' and 'anti-IgE therapy'.
- Included 19 RCTs evaluating omalizumab's impact on asthma control, corticosteroid use, and patient-reported outcomes.
- Extracted data on efficacy, safety, tolerability, and cost-effectiveness.
Main Results:
- Omalizumab treatment significantly improves symptom control in adults, adolescents, and children with poorly controlled IgE-mediated asthma.
- Patients receiving omalizumab can often be managed with lower doses of inhaled corticosteroids (ICS).
- Omalizumab is generally well-tolerated, with common side effects including injection-site reactions; rare cases of anaphylaxis were reported. Expert panel recommends omalizumab for specific patient subgroups.
Conclusions:
- Anti-IgE therapy with omalizumab offers an effective and generally safe treatment option for patients with IgE-mediated asthma unresponsive to conventional therapies.
- The benefits of omalizumab must be balanced against its cost and the practical aspects of administration.
- Omalizumab represents a valuable therapeutic advance for select patients with severe allergic asthma.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Nursing Management
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...